» Articles » PMID: 19924273

Protein-mediated Fatty Acid Uptake in the Heart

Overview
Date 2009 Nov 20
PMID 19924273
Citations 16
Authors
Affiliations
Soon will be listed here.
Abstract

Long chain fatty acids (LCFAs) provide 70-80% of the energy for cardiac contractile activity. LCFAs are also essential for many other cellular functions, such as transcriptional regulation of proteins involved in lipid metabolism, modulation of intracellular signalling pathways, and as substrates for membrane constituents. When LCFA uptake exceeds the capacity for their cardiac utilization, the intracellular lipids accumulate and are thought to contribute to contractile dysfunction, arrhythmias, cardiac myocyte apoptosis and congestive heart failure. Moreover, increased cardiac myocyte triacylglycerol, diacylglycerol and ceramide depots are cardinal features associated with obesity and type 2 diabetes. In recent years considerable evidence has accumulated to suggest that, the rate of entry of long chain fatty acids (LCFAs) into the cardiac myocyte is a key factor contributing to a) regulating cardiac LCFA metabolism and b) lipotoxicity in the obese and diabetic heart. In the present review we i) examine the evidence indicating that LCFA transport into the heart involves a protein-mediated mechanism, ii) discuss the proteins involved in this process, including FAT/CD36, FABPpm and FATP1, iii) discuss the mechanisms involved in regulating LCFA transport by some of these proteins (including signaling pathways), as well as iv) the possible interactions of these proteins in regulating LCFA transport into the heart. In addition, v) we discuss how LCFA transport and transporters are altered in the obese/diabetic heart.

Citing Articles

PEDF Overexpression Ameliorates Cardiac Lipotoxicity in Diabetic Cardiomyopathy via Regulation of Energy Metabolism.

Mao T, Wang Y Diabetes Metab Syndr Obes. 2025; 18:217-231.

PMID: 39896707 PMC: 11784309. DOI: 10.2147/DMSO.S482346.


Atrioventricular node dysfunction in pressure overload-induced heart failure-Involvement of the immune system and transcriptomic remodelling.

Wilson C, Zi M, Smith M, Hussain M, DSouza A, Dobrzynski H Front Pharmacol. 2023; 14:1083910.

PMID: 37081960 PMC: 10110994. DOI: 10.3389/fphar.2023.1083910.


Evogliptin, a DPP-4 inhibitor, prevents diabetic cardiomyopathy by alleviating cardiac lipotoxicity in db/db mice.

Pham T, Nguyen T, Yi J, Kim G, Yun H, Kim H Exp Mol Med. 2023; 55(4):767-778.

PMID: 37009790 PMC: 10167305. DOI: 10.1038/s12276-023-00958-6.


Visualizing increased uptake of [18F]FDG and [18F]FTHA in kidneys from obese high-fat diet fed C57BL/6J mice using PET/CT ex vivo.

Nyren R, Scherman H, Axelsson J, Chang C, Olivecrona G, Ericsson M PLoS One. 2023; 18(2):e0281705.

PMID: 36787333 PMC: 9928095. DOI: 10.1371/journal.pone.0281705.


Even chained acylcarnitines predict long-term cardiovascular prognosis in patients with chest pain and non-obstructive coronary artery disease.

Storesund S, Karaji I, Strand E, Svardal A, Lonnebakken M, Berge R Int J Cardiol Cardiovasc Risk Prev. 2022; 14:200134.

PMID: 35647612 PMC: 9136115. DOI: 10.1016/j.ijcrp.2022.200134.


References
1.
Hirooka K, Yasumura Y, Ishida Y, Komamura K, Hanatani A, Nakatani S . Improvement in cardiac function and free fatty acid metabolism in a case of dilated cardiomyopathy with CD36 deficiency. Jpn Circ J. 2000; 64(9):731-5. DOI: 10.1253/jcj.64.731. View

2.
Black P, DiRusso C . Yeast acyl-CoA synthetases at the crossroads of fatty acid metabolism and regulation. Biochim Biophys Acta. 2006; 1771(3):286-98. DOI: 10.1016/j.bbalip.2006.05.003. View

3.
Yamashita S, Hirano K, Kuwasako T, Janabi M, Toyama Y, Ishigami M . Physiological and pathological roles of a multi-ligand receptor CD36 in atherogenesis; insights from CD36-deficient patients. Mol Cell Biochem. 2006; 299(1-2):19-22. DOI: 10.1007/s11010-005-9031-4. View

4.
Finck B, Lehman J, Leone T, Welch M, Bennett M, Kovacs A . The cardiac phenotype induced by PPARalpha overexpression mimics that caused by diabetes mellitus. J Clin Invest. 2002; 109(1):121-30. PMC: 150824. DOI: 10.1172/JCI14080. View

5.
Kuang M, Febbraio M, Wagg C, Lopaschuk G, Dyck J . Fatty acid translocase/CD36 deficiency does not energetically or functionally compromise hearts before or after ischemia. Circulation. 2004; 109(12):1550-7. DOI: 10.1161/01.CIR.0000121730.41801.12. View